TOLREMO therapeutics have raised CHF 9 million in Series A fundraising
We are delighted to announce the closure of the Series A financing round for TOLREMO therapeutics, a Zurich-based biotech company developing a unique platform to generate treatments against cancer drug resistance.
Today, there is a high unmet need for durable therapeutic options for cancer patients, as current drugs often lose their effectiveness over time. Drug resistance therefore remains a major limiting factor to patient survival. TOLREMO’s platform has the potential to introduce a paradigm shift in cancer treatment by generating novel therapies targeting the resistance-causing molecular mechanisms right from the start. By combining TOLREMO's resistance-breaking add-on compounds with existing cancer drugs and a proprietary screening platform, the company aims to extend the therapeutic benefit of existing cancer therapeutics.
The oversubscribed CHF 9 million Series A financing round, led by the Swiss venture capital firm BioMedPartners, was joined by Redalpine and Altos Venture, as well as TOLREMO’s existing shareholders. The capital increase will allow the ETH spin-off TOLREMO to rapidly advance their preclinical development programs. TOLREMO further strengthened its Board of Directors with the addition of world-leading industry experts Dr. Erich Greiner and Prof. em. Thomas Cerny, as well as Dr. Andreas Wallnöfer, General Partner at BioMedPartners.
For more information, please visit www.tolremo.com.